Elsevier Launches Current Opinion in Virology

AMSTERDAM, July 12, 2011 -

- Helping Virologists Keep
Up-to-Date in a Fast-moving
Field

Elsevier ( href="www.elsevier.com/">www.elsevier.com) has
announced the publication of the first issue of Current Opinion
in Virology - a new journal in its prestigious Current Opinion
series, publishing six issues a year. Current Opinion in
Virology was launched to provide a systematic, comprehensive
and filtered approach to the ever-expanding wealth of research
published on viruses and viral interaction: a platform to help busy
specialists keep up-to-date with the latest trends and topics in
virology research. The journal publishes invited review papers only
and is divided into twelve annual sections, including viral
genomics, antivirals and resistance, emerging viruses and virus
evolution.

The editorial board is led by Editors in Chief Mary Estes
(Baylor College of Medicine, USA) and Ab Osterhaus (Erasmus MC, The
Netherlands). “Virology is a discipline that is dynamic,
multidisciplinary and important to our lives in many ways,” states
Dr. Estes. “When approached about starting a new journal in
virology, we came to the conclusion that the principle and quality
of the Current Opinion series in other topics made it an
attractive medium to communicate new information in a broad range
of virology topics. Looking beyond the successful launch of the
journal,” Dr Estes concluded, “we look forward, as the virology
field, technologies and world continues to change, to Current
Opinion in Virology becoming one of the most highly respected
journals in the field.”

All articles in the first issue are freely available online ( href="www.sciencedirect.com/science/journal/18796257">www.sciencedirect.com/science/journal/18796257
). More information on the journal can be found on the website href="www.current-opinion.com/journals/current-opinion-in-virology">
www.current-opinion.com/journals/current-opinion-in-virology.

About Elsevier

Elsevier is a world-leading provider of scientific, technical
and medical information products and services. The company works in
partnership with the global science and health communities to
publish more than 2,000 journals, including href="www.thelancet.com/">The Lancet and href="www.cell.com/">Cell, and close to 20,000
book titles, including major reference works from Mosby and
Saunders. Elsevier’s online solutions include href="www.sciencedirect.com/">SciVerse ScienceDirect, href="www.scopus.com/">SciVerse Scopus, href="www.reaxys.com/">Reaxys, href="www.mdconsult.com/">MD Consult and href="www.nursingconsult.com/">Nursing Consult, which
enhance the productivity of science and health professionals, and
the SciVal suite and href="www.medai.com/">MEDai’s Pinpoint Review, which
help research and health care institutions deliver better outcomes
more cost-effectively.

A global business headquartered in Amsterdam, href="www.elsevier.com/">Elsevier employs 7,000 people
worldwide. The company is part of href="www.reedelsevier.com/">Reed Elsevier Group PLC, a
world-leading publisher and information provider, which is jointly
owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols
are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and
ENL (New York Stock Exchange).

Media Contact
Alina Helsloot
href="mailto:a.helsloot@elsevier.com">a.helsloot@elsevier.com

Phone +31-20-485-3835
Elsevier

.